Self-assembled micelles of amphiphilic PEGylated rapamycin for loading paclitaxel and resisting multidrug resistant cancer cells†Electronic supplementary information (ESI) available: Chemicals and reagents, detailed experimental procedures for materials synthesis, characterization, cellular evaluations and supporting figures and tables. See DOI: 10.1039/c4tb01633eClick here for additional data file

Wei Tian; Jieying Liu; Yuan Guo; Yuanyuan Shen; Dejian Zhou; Shengrong Guo

doi:10.1039/c4tb01633e

Self-assembled micelles of amphiphilic PEGylated rapamycin for loading paclitaxel and resisting multidrug resistant cancer cells†Electronic supplementary information (ESI) available: Chemicals and reagents, detailed experimental procedures for materials synthesis, characterization, cellular evaluations and supporting figures and tables. See DOI: 10.1039/c4tb01633eClick here for additional data file

J Mater Chem B. 2015 Feb 21;3(7):1204-1207. doi: 10.1039/c4tb01633e. Epub 2015 Jan 27.

Authors

Wei Tian¹, Jieying Liu¹, Yuan Guo², Yuanyuan Shen¹, Dejian Zhou², Shengrong Guo³

Affiliations

¹ School of Pharmacy , Shanghai Jiao Tong University , Shanghai , 200240 , China.
² School of Chemistry and Asbury Centre for Structural Molecular Biology , University of Leeds , Leeds , LS2 9JT , UK . Email: d.zhou@leeds.ac.uk ; Email: s.guo@leeds.ac.uk ; Email: srguo@sjtu.edu.cn ; Tel: +44 (0)113 3436230 ; Tel: +44 (0)113 3436449.
³ School of Pharmacy , Shanghai Jiao Tong University , Shanghai , 200240 , China ; School of Chemistry and Asbury Centre for Structural Molecular Biology , University of Leeds , Leeds , LS2 9JT , UK . Email: d.zhou@leeds.ac.uk ; Email: s.guo@leeds.ac.uk ; Email: srguo@sjtu.edu.cn ; Tel: +44 (0)113 3436230 ; Tel: +44 (0)113 3436449.

Abstract

Self-assembled micelles of amphiphilic PEG-rapamycin conjugates loaded with paclitaxel have been developed for co-delivery and simultaneous intracellular release of paclitaxel and rapamycin, bypassing the cancer cell drug resistant mechanism and maximising the synergy of dual-drug combinational therapy. This novel nanomedicine offers 20-fold improved potency over free paclitaxel against a model multidrug resistant human breast cancer cell.